ENhanced Recovery in CHildren Undergoing Surgery
| Condition | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis |
|---|---|
| Phase | Phase 3 |
| Sponsor | Northwestern University |
| Status | Completed |
| Enrollment | 597 participants |
| Interventions | Perioperative surgical care |
| Start date | Jul 1, 2020 |
| Completion date | Nov 6, 2024 |
| Results posted | Jun 23, 2026 |
Summary
The institution of perioperative Enhanced Recovery Protocols (ERPs) has been found to decrease hospital length of stay, in-hospital costs, and complications among adult surgical populations but data in pediatric populations are lacking. The Assessing Effectiveness and Implementation of a Perioperative Enhanced Recovery Protocol for Children Undergoing Gastrointestinal Surgery, which has the short title "ENhanced Recovery In CHildren Undergoing Surgery (ENRICH-US)," study is a multicenter, pragmatic, prospective study, using a stepped wedge cluster randomized controlled trial design. The study is designed to test the adoption, effectiveness, and generalizability of a newly developed, 21-element ERP for children undergoing elective gastrointestinal surgery.
Length of Stay (LOS)
| Baseline (Pre-Implementation) | 4 Days |
|---|---|
| Implementation | 4 Days |
| Sustainability | 4 Days |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Act — Janssen Research & Development, LLC
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severe — Janssen Research & Development, LLC
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn' — Janssen Research & Development, LLC
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Partic — Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Celularity Incorporated
- Loss of RESponse to Ustekinumab Treated by Dose Escalation — Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW